TY  - JOUR
AU  - Van Cutsem, Eric
AU  - Martinelli, Erika
AU  - Cascinu, Stefano
AU  - Sobrero, Alberto
AU  - Banzi, Maria
AU  - Seitz, Jean-François
AU  - Barone, Carlo
AU  - Ychou, Marc
AU  - Peeters, Marc
AU  - Brenner, Baruch
AU  - Hofheinz, Ralf Dieter
AU  - Maiello, Evaristo
AU  - André, Thierry
AU  - Spallanzani, Andrea
AU  - Garcia-Carbonero, Rocio
AU  - Arriaga, Yull E
AU  - Verma, Udit
AU  - Grothey, Axel
AU  - Kappeler, Christian
AU  - Miriyala, Ashok
AU  - Kalmus, Joachim
AU  - Falcone, Alfredo
AU  - Zaniboni, Alberto
PY  - 2018
DO  - 10.1634/theoncologist.2018-0072
UR  - http://hdl.handle.net/10668/12916
T2  - The oncologist
AB  - In the phase III CORRECT trial, regorafenib significantly improved survival in treatment-refractory metastatic colorectal cancer (mCRC). The CONSIGN study was designed to further characterize regorafenib safety and allow patients access to regorafenib...
LA  - en
KW  - Metastatic colorectal cancer
KW  - Prospective studies
KW  - Regorafenib
KW  - Toxicities
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Colorectal Neoplasms
KW  - Disease Progression
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Phenylurea Compounds
KW  - Prospective Studies
KW  - Pyridines
TI  - Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
TY  - research article
VL  - 24
ER  -